Frontier Biotechnologies Inc. Class A
SSSE:68822113.61
CNY
-0.59
(-4.15%)
ISIN
CNE100005XF5
Return %
Stock
S&P 500
1Y
-5.94
14.20
3Y
35.29
81.12
5Y
-15.99
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- Full Time Employees
- 314
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Nanjing China
- IPO Date
- Oct 28, 2020
- Website
- frontierbiotech.com
- Similar Companies
- Business
- Frontier Biotechnologies Inc. is a commercial-stage biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative human therapeutics, specializing in long-acting peptide drugs, transdermal delivery systems, and small interfering RNA (siRNA) therapies for antiviral, pain management, and chronic disease indications. Founded in 2013 and headquartered in Nanjing, China, the company maintains research, clinical development, and cGMP-compliant manufacturing infrastructure across facilities in Nanjing, Sichuan, and Shandong, while supporting clinical and commercialization initiatives across Greater China, the United States, Southeast Asia, Central Asia, and Latin America. The company's primary product and service offerings comprise: Aikening (albuvirtide for injection), a proprietary, weekly administered injectable HIV-1 fusion inhibitor approved for the treatment of HIV-1 infection, particularly in treatment-experienced, multi-drug resistant, and perioperative patient populations; FB4001, a generic teriparatide injectable therapeutic developed for the management of osteoporosis, under Abbreviated New Drug Application (ANDA) review with the U.S. Food and Drug Administration; FB3001, an advanced topical transdermal patch formulation indicated for localized musculoskeletal disorders and chronic back pain management; investigational small interfering RNA (siRNA) candidate programs, including early-stage therapeutic assets designed for chronic kidney and metabolic diseases; and integrated biopharmaceutical development, contract formulation, and cGMP manufacturing services leveraging its proprietary long-acting peptide modification and transdermal drug delivery platforms. In recent corporate developments, Frontier Biotechnologies has executed significant strategic partnerships and pipeline realignments to accelerate commercial expansion and focus resources on core high-value programs. The company entered into an exclusive global licensing agreement with GlaxoSmithKline (GSK) covering two preclinical siRNA therapeutic candidates for kidney disease indications, granting GSK exclusive worldwide rights to develop, manufacture, and commercialize the assets in exchange for upfront and contingent milestone payments totaling up to 1.0 billion USD, plus tiered sales royalties. Concurrently, the company completed a strategic portfolio restructuring by terminating the development of legacy programs, including the FB1002 long-acting injectable HIV combination therapy and the FB2001 COVID-19 protease inhibitor asset, reallocating capital and operational focus toward its commercial Aikening operations, transdermal patch development, and proprietary oligonucleotide technologies, while expanding the regulatory registration and commercial distribution network for Aikening across overseas markets including Ecuador, Cambodia, Malaysia, Kazakhstan, and Azerbaijan.